INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 410m ago
HOUSE PTR10m ago
SEC 13F10m ago
ROBINHOOD CHAIN9m ago
SEC FORM 4/Open-market saleVerified data

Leupin Nicolas sold NVCR

Former Chief Medical Officer · NovoCure Ltd · Ordinary Shares

Side
SELL
Value
$15K
Shares
1,100
Price
$13.31
Executed
Mar 4, 2026
Disclosed
Mar 5, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Mar 4 executedMar 5, 2026 disclosed

NVCR · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
36/ 100 · ELEVATED
Methodology →
  • Transaction type+12 / 20

    Open-market sale

  • Relative size+1 / 25

    $15K reported value · 1.1% of prior position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering+15 / 15

    3 other actors traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · NVCR

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    17
    PN
    Puri Michal NathChief Human Resources Officer
    NVCRNovoCure Ltd
    Open-market sale
    		SELL$8,738
    660 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    5
    PN
    Puri Michal NathChief Human Resources Officer
    NVCRNovoCure Ltd
    Grant or award
    		A$21K
    1,905 sh
    		Jun 30, 2026Jul 1, 2026
    traded Jun 30, 2026
    		+1dSEC FORM 4

    Evidence

    9
    BB
    Ben Arye BarakGeneral Counsel
    NVCRNovoCure Ltd
    Grant or award
    		A$14K
    1,299 sh
    		Jun 30, 2026Jul 1, 2026
    traded Jun 30, 2026
    		+1dSEC FORM 4

    Evidence

    21
    SK
    Stafford KristinDirector
    NVCRNovoCure Ltd
    Grant or award
    		A—
    11.6K sh
    		Jun 3, 2026Jun 5, 2026
    traded Jun 3, 2026
    		+2dSEC FORM 4

    Evidence

    9
    OJ
    Ocean Allyson JDirector
    NVCRNovoCure Ltd
    Grant or award
    		A—
    17.0K sh
    		Jun 3, 2026Jun 5, 2026
    traded Jun 3, 2026
    		+2dSEC FORM 4

    Evidence

    9
    SK
    Stafford KristinDirector
    NVCRNovoCure Ltd
    Grant or award
    		A—
    17.0K sh
    		Jun 3, 2026Jun 5, 2026
    traded Jun 3, 2026
    		+2dSEC FORM 4

    Evidence

    21
    OJ
    Ocean Allyson JDirector
    NVCRNovoCure Ltd
    Grant or award
    		A—
    11.6K sh
    		Jun 3, 2026Jun 5, 2026
    traded Jun 3, 2026
    		+2dSEC FORM 4

    Evidence

    9
    PM
    Paravasthu MukundChief Operating Officer
    NVCRNovoCure Ltd
    Grant or award
    		A—
    7,518 sh
    		Mar 3, 2026Mar 5, 2026
    traded Mar 3, 2026
    		+2dSEC FORM 4

    Evidence

    21
    PM
    Paravasthu MukundChief Operating Officer
    NVCRNovoCure Ltd
    Grant or award
    		A—
    58.5K sh
    		Mar 3, 2026Mar 5, 2026
    traded Mar 3, 2026
    		+2dSEC FORM 4

    Evidence

    17
    PN
    Puri Michal NathChief Human Resources Officer
    NVCRNovoCure Ltd
    Grant or award
    		A—
    40.1K sh
    		Mar 3, 2026Mar 5, 2026
    traded Mar 3, 2026
    		+2dSEC FORM 4

    Evidence

    36
    PN
    Puri Michal NathChief Human Resources Officer
    NVCRNovoCure Ltd
    Open-market sale
    		SELL$15K
    1,100 sh
    		Mar 4, 2026Mar 5, 2026
    traded Mar 4, 2026
    		+1dSEC FORM 4

    Evidence

    9
    PN
    Puri Michal NathChief Human Resources Officer
    NVCRNovoCure Ltd
    Grant or award
    		A—
    58.7K sh
    		Mar 3, 2026Mar 5, 2026
    traded Mar 3, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BB
    Ben Arye BarakGeneral Counsel
    NVCRNovoCure Ltd
    Grant or award
    		A—
    73.3K sh
    		Mar 3, 2026Mar 5, 2026
    traded Mar 3, 2026
    		+2dSEC FORM 4

    Evidence

    17
    BB
    Ben Arye BarakGeneral Counsel
    NVCRNovoCure Ltd
    Grant or award
    		A—
    50.1K sh
    		Mar 3, 2026Mar 5, 2026
    traded Mar 3, 2026
    		+2dSEC FORM 4

    Evidence

    39
    BC
    Brackmann ChristophChief Financial Officer
    NVCRNovoCure Ltd
    Open-market sale
    		SELL$85K
    6,412 sh
    		Mar 4, 2026Mar 5, 2026
    traded Mar 4, 2026
    		+1dSEC FORM 4

    Evidence

    17
    BC
    Brackmann ChristophChief Financial Officer
    NVCRNovoCure Ltd
    Grant or award
    		A—
    55.1K sh
    		Mar 3, 2026Mar 5, 2026
    traded Mar 3, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BC
    Brackmann ChristophChief Financial Officer
    NVCRNovoCure Ltd
    Grant or award
    		A—
    80.7K sh
    		Mar 3, 2026Mar 5, 2026
    traded Mar 3, 2026
    		+2dSEC FORM 4

    Evidence

    21
    PM
    Paravasthu MukundChief Operating Officer
    NVCRNovoCure Ltd
    Grant or award
    		A—
    45.1K sh
    		Mar 3, 2026Mar 5, 2026
    traded Mar 3, 2026
    		+2dSEC FORM 4

    Evidence

    39
    PM
    Paravasthu MukundChief Operating Officer
    NVCRNovoCure Ltd
    Open-market sale
    		SELL$72K
    5,377 sh
    		Mar 4, 2026Mar 5, 2026
    traded Mar 4, 2026
    		+1dSEC FORM 4

    Evidence

    46
    PM
    Paravasthu MukundChief Operating Officer
    NVCRNovoCure Ltd
    Open-market sale
    		SELL$596K
    43.2K sh
    		Mar 5, 2026Mar 5, 2026
    traded Mar 5, 2026
    		+0dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002007766-26-000003
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Mar 4, 2026
    Published
    Mar 5, 2026
    Ingested by INSIDER
    Nov 5, 04:13 UTC
    Last re-read
    Nov 5, 04:13 UTC

    Extracted facts

    Filer
    Leupin Nicolas
    Role
    Former Chief Medical Officer
    Transaction
    Open-market saleAs filed: “S”
    Asset
    NovoCure Ltd
    Ticker
    NVCR
    Shares
    1,100
    Price per share
    $13.31
    Value
    $14,636
    Execution date (reported)
    Mar 4, 2026
    Owned after transaction
    103.0K shares
    Days from execution to publication
    1

    Calculation

    Value = shares × reported price per share

    • Shares: 1,100
    • Price: $13.3054

    = $14,636

    What this establishes

    Leupin Nicolas filed this Form 4 reporting a open-market sale of NVCR on Mar 4, 2026. It became public on Mar 5, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Former Chief Medical Officer
    Leupin Nicolascik:0002007766
    Issuer
    NovoCure Ltdcik:0001645113

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.